Announcement
Collapse
No announcement yet.
Limey Lang
Collapse
-
-
-
Study Design
This study consisted of 2 separate substudies: one
evaluating PD parameters (ie, hemodynamics) and one
evaluating PK parameters.
The PD study was conducted as a double-blind,
randomized, 2-period, 2-treatment, 2-sequence, doubledummy,
single-dose crossover design with S-amlodipine
(S-amlodipine gentisate) and amlodipine racemate
(amlodipine besylate). All volunteers were randomly
assigned to a sequence group for the 2 treatments according
to a randomization table. A number was sequentially
assigned to all volunteers who met the eligibility
criteria, according to the order of ECG measurements.
Each sequence group consisted of 12 volunteers. The
volunteers in each group were admitted on the day
before study and fasted for 10 hours before dosing.
On the next day, baseline evaluations were performed
just before dosing. For one sequence group, the volunteers
received a single oral dose of S-amlodipine 5 mg
(two 2.5-mg tablets) and amlodipine racemate matching
placebo (2 tablets) with 240 mL of water at ~9 am.
They were maintained in the semi-Fowler position
and in the fasting state until 4 hours after drug administration.
BP, heart rate, and impedance cardiography
(ICG) were performed repeatedly during hospitalization
(see “Pharmacodynamic Assessment”) for the
evaluation of PD parameters. The volunteers were
discharged on the morning of the day after dosing,
and they returned on 2 successive mornings for PD
evaluations. Two weeks after the first dosing, a single
dose of amlodipine racemate 10 mg (two 5-mg tablets)
and S-amlodipine matching placebo (2 tablets)
were administered orally to the volunteers with 240 mL
of water. The other sequence group received the opposite
order of treatments; however, in both groups,
the study schedules were the same for each treatment
period.
The design of the PK study was the same as for the
PD study, and the schedules of hospitalization, administration,
and fasting were also the same. The volunteers in the PK study were different from those in the
PD study. A total of 24 volunteers participated, with
12 in each sequence group. For one sequence group, the
volunteers were given a single oral dose of S-amlodipine
5 mg (two 2.5-mg tablets) and amlodipine racemate
matching placebo (2 tablets) with 240 mL of water at
~9 am. Serial blood samples for the evaluation of PK
parameters were collected during hospitalization (see
“Pharmacokinetic Assessment”). The volunteers were
discharged on the morning of the day after dosing,
and they returned every morning for 6 days for PK
evaluations. Two weeks after the first dosing, they
were administered a single dose of amlodipine racemate
10 mg (two 5-mg tablets) and S-amlodipine
matching placebo (2 tablets) with 240 mL of water.
The other sequence group received the opposite order
of treatments; however, in both groups, the study
schedules were the same for each treatment period.
Comment
-
-
Comment